PubAg

Main content area

Synthetic astaxanthin is significantly inferior to algal-based astaxanthin as an antioxidant and may not be suitable as a human nutraceutical supplement

Author:
Capelli, Bob, Bagchi, Debasis, Cysewski, Gerald R.
Source:
NUTRAfoods 2013 v.12 no.4 pp. 145-152
ISSN:
1827-8590
Subject:
Haematococcus pluvialis, antioxidant activity, astaxanthin, beta-carotene, canthaxanthin, clinical trials, esterification, functional foods, humans, in vitro studies, ingredients, microalgae, singlet oxygen, stereochemistry
Abstract:
Synthetic astaxanthin (S-AX) was tested against natural astaxanthin from Haematococcus pluvialis microalgae (N-AX) for antioxidant activity. In vitro studies conducted at Creighton University and Brunswick Laboratories showed N-AX to be over 50 times stronger than S-AX in singlet oxygen quenching and approximately 20 times stronger in free radical elimination. N-AX has been widely used over the last 15 years as a human nutraceutical supplement after extensive safety data and several health benefits were established. S-AX, which is synthesised from petrochemicals, has been used as a feed ingredient, primarily to pigment the flesh of salmonids. S-AX has never been demonstrated to be safe for use as a human nutraceutical supplement and has not been tested for health benefits in humans. Due to safety concerns with the use of synthetic forms of other carotenoids such as canthaxanthin and beta-carotene in humans, the authors recommend against the use of S-AX as a human nutraceutical supplement until extensive, long-term safety parameters have been established and human clinical trials have been conducted showing potential health benefits. Additionally, differences in various other properties between SAX and N-AX such as stereochemistry, esterification and the presence of supporting naturally occurring carotenoids in N-AX are discussed, all of which elicit further questions as to the safety and potential health benefits of S-AX. Ultimately, should S-AX prove safe for direct human consumption, dosage levels roughly 20–30 times greater than N-AX should be used as a result of the extreme difference in antioxidant activity between the two forms.
Agid:
374744